Analytical Data
-
基因名
DEFa4
- Application
-
别名
DEFa4；DEF4；Defensin alpha 4
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P12838
-
表达区间
1-97aa
-
氨基酸序列
MRIIALLAAILLVALQVRAGPLQARGDEAPGQEQRGPEDQDISISFAWDKSSALQVSGSTRGMVCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRVD
-
分子量
10.5 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DEFa4 is a member of the defensin family, which are small, cationic peptides that play a critical role in the innate immune response by exhibiting antimicrobial properties against a wide range of pathogens. The interest in DEFa4 has surged due to its potential therapeutic applications, particularly in the treatment of infections and inflammatory diseases. Research has shown that DEFa4 can disrupt bacterial membranes, inhibit viral replication, and modulate immune responses, making it a promising candidate for developing new antimicrobial agents. Furthermore, the recombinant production of DEFa4 allows for more extensive studies into its structure-function relationships, stability, and interaction with various pathogens. Advances in genetic engineering and protein purification techniques have facilitated the reliable production of this peptide, enabling scientists to explore its efficacy and safety in vivo. Additionally, understanding DEFa4's mechanisms of action may lead to the design of novel antibiotics in an era of increasing antibiotic resistance. As such, DEFa4 continues to be a focal point of research aimed at harnessing its antimicrobial properties and elucidating its potential roles in immune modulation, paving the way for innovative therapeutic strategies.
